Select your language

ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)

cover biotech acta general

Biotechnologia Acta Т. 16, No. 5 , 2023
P. 55-60, Bibliography 17, Engl.
UDC:: 57.088.2
DOI: https://doi.org/10.15407/biotech16.05.055

Full text: (PDF, in English)

APROBATION OF PLATELET AGGREGATION INHIBITOR FROM ECHIS MULTISQUAMATIS SNAKE VENOM IN VITRO, IN VIVO AND EX VIVO

 Zhelavskyi M.A.1, 2, Platonov M.O.1, Kucheryavyi Y.Р.1, Stohnii Y.M. 1

1. Palladin Institute of biochemistry of National Academy of Sciences of Ukraine, Kyiv
2. ZL “Success Academy”, Kyiv region, Ukraine

Snake venom-derived platelet aggregation inhibitors can be promising antiplatelet medications that can allow to avoid the risk of bleeding and treatment resistance, particularly in aspirin-resistant patients. Our study aimed to assess the effectiveness of a platelet aggregation inhibitor derived from Echis multisquamatis snake venom in various settings, including in vitro, in vivo, and ex vivo.

Methods. We examined a polypeptide from Echis multisquamatis venom, purified using a recently developed chromatography protocol, across multiple models. This polypeptide was introduced into platelet-rich blood plasma and administered intravenously to rats. The effects on platelet aggregation were assessed using aggregometry, focusing on ADP-induced aggregation.

Results & Discussion. Our findings revealed that a concentration of 0.040 mg/ml significantly reduced platelet aggregation in vitro. Remarkably, this dosage also proved effective when administered intravenously in laboratory animals, reaffirming its potential as a robust antiplatelet agent. In the final phase of our study, the polypeptide demonstrated its ability to inhibit platelet aggregation in the blood plasma of pregnant women with aspirin resistance, presenting a promising avenue for innovative treatment approaches in such cases.

Conclusion. This study underscores the potential of the Echis multisquamatis venom-derived polypeptide as a promising antiplatelet agent, effective in diverse scenarios, including aspirin resistance. Further research and clinical trials are imperative to harness its therapeutic potential fully..

 Key words: disintegrin, blood plasma, platelets, thrombosis, blood coagulation, platelet aggregation, animal model.

© Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, 2023